Insider trading

Period: 120 months Stock: DGX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

182 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

182 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

182 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

182 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
182 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
182 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

182 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
27 Feb 2018
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$129.92K 1,248 at 104.10
1.8%
27 Feb 2018
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$119.72K 1,150 at 104.10
3.0%
27 Feb 2018
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$96.50K 927 at 104.10
2.3%
26 Feb 2018
Klug Robert A VP, Corporate Controller
Sold, plan not stated
$119.93K 1,157 at 103.66
22.9%
26 Feb 2018
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$50.75K 494 at 102.74
1.2%
26 Feb 2018
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$40.79K 397 at 102.74
0.6%
29 Jan 2018
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$11.43M 106,840 at 107.00
39.1%
24 Jan 2018
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$2.21M 21,294 at 104.00
23.5%
2 Jan 2018
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$6.30M 63,880 at 98.68
62.7%
Sold half or more
12 Sep 2017
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$573.24K 5,302 at 108.12
3.1%
11 Sep 2017
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$5.83M 53,933 at 108.16
24.5%
11 Sep 2017
STANZIONE DANIEL Director
Sold, plan not stated
$4.42M 40,900 at 108.07
54.1%
Sold half or more
5 Sep 2017
STANZIONE DANIEL Director
Sold, plan not stated
$410.76K 3,803 at 108.01
9.9%
5 Sep 2017
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$272.77K 2,525 at 108.03
1.5%
4 Aug 2017
LEIDEN JEFFREY M Director
Sold, plan not stated
$31.57K 296 at 106.66
4.7%
27 Jul 2017
LEIDEN JEFFREY M Director
Sold, plan not stated
$141.78K 1,304 at 108.73
17.2%
19 Jun 2017
Cohen Jon R SVP & Group Exec. Diag. Sol.
Sold, plan not stated 6×
$11.50M 106,900 at 107.55
59.4%
Sold half or more
19 Jun 2017
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 6×
$6.43M 59,762 at 107.55
46.3%
24 Apr 2017
BRITELL JENNE K Director · indirect
Sold, plan not stated
$635.73K 6,111 at 104.03
23.5%
20 Apr 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated 2×
$2.95M 29,513 at 100.00
42.3%
16 Mar 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$1.40M 13,987 at 100.00
25.8%
3 Mar 2017
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$592.49K 6,028 at 98.29
7.5%
3 Mar 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$440.14K 4,478 at 98.29
10.0%
2 Mar 2017
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$111.42K 1,134 at 98.25
1.4%
1 Mar 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$45.95K 470 at 97.77
1.2%
27 Feb 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$42.85K 440 at 97.39
1.1%
22 Feb 2017
ZIEGLER JOHN B Director
Sold, plan not stated
$191.02K 2,000 at 95.51
10.8%
15 Feb 2017
Doherty Catherine T. SVP, Clin. Franchise Solutions
Sold, plan not stated
$152.86K 1,615 at 94.65
2.2%
13 Feb 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$112.51K 1,200 at 93.76
2.9%
2 Feb 2017
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated 2×
$4.16M 45,000 at 92.39
51.8%
Sold half or more
30 Jan 2017
Doherty Catherine T. SVP, Clin. Franchise Solutions
Sold, plan not stated 3×
$7.25M 80,000 at 90.58
51.0%
Sold half or more
15 Nov 2016
PFEIFFER GARY M Director
Sold, plan not stated 6×
$3.63M 42,643 at 85.09
75.7%
Sold half or more
Showing 151–182 of 182. ← Newer Page 4 of 4